Shaun Grady is responsible for representing AstraZeneca’s whole enterprise across the UK. In this role, reporting to CEO Pascal Soriot, Shaun works closely with relevant senior leaders across AstraZeneca to champion and support our science and R&D function, operations and manufacturing, commercial business, and our corporate priorities across the life sciences ecosystem in the UK.
Shaun also manages critical relationships with senior Government representatives, business leaders and industry associations, as well as leading on advocacy for key policy priorities. As UK Chair he also represents AstraZeneca’s global enterprise, where we support and leverage the UK's unique diplomatic and economic networks to improve trade and international cooperation in life sciences. Additionally, Shaun chairs the UK Leadership Team, the UK Employee Forum and the UK Inclusion and Diversity working group.
Before becoming the Chair of AstraZeneca UK, Shaun led the company’s business development function where he has worked for over 20 years, and before that was a member of the legal team working on corporate transactions. Shaun has played a central role in almost every major business development activity during his time with the company, including the merger of Astra and Zeneca, the acquisition of Cambridge Antibody Technology (CAT), and later MedImmune and Amylin, and the buy-out of Bristol-Myers’ Squibb’s interest in the AstraZeneca-BMS Diabetes Alliance. More recently, Shaun led the transaction team for AstraZeneca’s global ADC collaborations with Daichi Sankyo, and the acquisition of Gracell, Icosovax and Fusion, as well as the collaboration with Ecogene.
Shaun is a Board member at the BioIndustry Association (BIA) and CBI President’s Committee, is Chairman of the Board of Directors of Cambridge United Football Club, and a Board member at Cambridge Arts Theatre, and at Prostate Cancer Research, as well as an Honorary Fellow at The University of Cambridge Judge Business School and Lucy Cavendish College Cambridge.